- Home
- HQL vs INBX Comparison
HQL vs INBX Comparison
Compare HQL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | INBX |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.2M | 430.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HQL | INBX |
|---|---|---|
| Price | $16.67 | $77.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 120.9K | ★ 247.1K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.34 | $10.81 |
| 52 Week High | $14.37 | $94.57 |
Technical Indicators
Market Signals| Indicator | HQL | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 47.21 |
| Support Level | $16.15 | $72.90 |
| Resistance Level | $17.29 | $80.00 |
| Average True Range (ATR) | 0.35 | 5.66 |
| MACD | -0.03 | -0.94 |
| Stochastic Oscillator | 43.80 | 28.59 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.